Welcome to our dedicated page for Aspira Women's Health news (Ticker: $AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women's Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aspira Women's Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aspira Women's Health's position in the market.
Rhea-AI Summary
Aspira Women’s Health Inc. announced a registered direct offering and concurrent private placement of 1,571,000 shares of its common stock at a combined purchase price of $3.50 per share to institutional investors and existing shareholders. CEO Nicole Sandford and certain existing shareholders will also participate in the purchase. The warrants will have exercise prices ranging from $4.00 to $4.13 per share, with expiration 5 years from the initial exercise date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
-
Rhea-AI Summary
Aspira Women’s Health Inc. (Nasdaq: AWH) to host virtual R&D day on January 4, 2024, featuring updates on the development of ovarian cancer and endometriosis tests. The event will showcase progress in the company’s product pipeline, including OvaWatch, OvaMDx, EndoCheck, and EndoMDx.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
-
Rhea-AI Summary
Aspira Women’s Health Inc. (AWH) will be available for meetings in San Francisco from January 8-10, 2024, during JP Morgan’s Healthcare Conference Week. Nicole Sandford, President and CEO, and Torsten Hombeck, CFO, will be attending the 12th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright & Co. Hosted Investor Meetings for partnering and institutional one-on-one meetings. Aspira is a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
Rhea-AI Summary
Aspira Women’s Health Inc. (Nasdaq: AWH) has developed EndoCheck, the first blood test for identifying localized endometriosis, including endometrioma, with plans for a commercial launch in 2024. The test is expected to offer a non-invasive alternative to laparoscopic surgery for endometriomas, potentially addressing a market of up to 2.5 million women in the U.S. The company is also working on the development of EndoMDx, a broader test for all types and locations of endometriosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
-
News
Rhea-AI Summary
Aspira Women’s Health Inc. (AWH) announced that California Medicaid (Medi-Cal) added Ova1Plus® to its fee schedule at $897 per test. Aspira will be reimbursed at a rate of $897 for all Ova1Plus® tests processed for Medi-Cal patients meeting applicable coverage requirements, effective from October 15, 2023. The addition of Ova1Plus® to the fee schedule provides expanded access to this groundbreaking technology for women in California facing an ovarian cancer diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
-
Rhea-AI Summary
Aspira Women’s Health Inc. (AWH) receives CMS approval for OvaWatch 2024 price at $897 per test. The Centers for Medicare & Medicaid Services (CMS) has approved the reimbursement rate for OvaWatch and Ova1 tests processed for Medicare patients, beginning January 1, 2024. Aspira's President and CEO, Nicole Sandford, emphasizes the importance of reliable clinical data in ovarian cancer diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
Rhea-AI Summary
Aspira Women’s Health Inc. (Nasdaq: AWH) reported a 9% increase in product revenue to $2.2 million for the quarter and a 19% increase to $7.0 million year to date. OvaSuite sales volume increased 5% to 5,783 units for the quarter and 16% to 18,331 units year to date. The company also highlighted significant achievements in the development of new products and the establishment of a Clinical Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
-
Rhea-AI Summary
Aspira Women’s Health Inc. (Nasdaq: AWH) announces that CMS has proposed to crosswalk the reimbursement rate for OvaWatch to Ova1 at $897 per test, pending finalization in January 2024. This move supports Aspira's mission to gain broad reimbursement coverage for their non-invasive ovarian cancer identification tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
-
Rhea-AI Summary
Aspira Women’s Health Inc. will report its financial results for the three months ended September 30, 2023 on November 13, 2023. The company will host a conference call with investors at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Participants can join the call using the provided toll-free and international numbers or access the event instantly through the Call me™ link. A replay of the webcast will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
Rhea-AI Summary
Aspira Women’s Health announces promising findings on an in-development miRNA-based ovarian cancer test. The study shows that miRNA has the potential to improve the diagnostic accuracy of non-invasive diagnostic tests for early-stage ovarian cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
Aspira Women's Health Inc.
Nasdaq:AWH
AWH Rankings
AWH Stock Data
39.62M
9.36M
38.84%
9.09%
1.09%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
AUSTIN
About AWH
vermillion, inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. the company’s initial in vitro diagnostic test, ova1®, was the first fda-cleared, protein-based in vitro diagnostic multivariate index assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. in march 2016 vermillion received fda clearance for overa™, a second generation ova1 test with significantly improved specificity and ease of use.